- News Home
10 April 2014 11:44 am ,
Vol. 344 ,
Balkan endemic kidney disease surfaced in the 1950s and for decades defied attempts to finger the cause. It occurred...
The Pyrenean ibex, an impressive mountain goat that lived in the central Pyrenees in Spain, went extinct in 2000. But a...
Tight budgets are forcing NASA to consider turning off one or more planetary science projects that have completed their...
Ebola is not a stranger to West Africa—an outbreak in the 1990s killed chimpanzees and sickened one researcher. But the...
In an as-yet-unpublished report, an international panel of geoscientists has concluded that a pair of deadly...
Tropical disease experts tried and failed before to eradicate yaws, a rare disfiguring disease of poor countries. Now,...
Since 2002, researchers have reported that agricultural communities in the hot and humid Pacific Coast of Central...
- 10 April 2014 11:44 am , Vol. 344 , #6180
- About Us
Keeping the Young from Dying Old
29 August 2005 (All day)
A class of drugs already under development for cancer may offer the first treatment for Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder in which children seem to age prematurely and typically die in their teens. Two research groups report this week that the drugs reverse a key cellular defect characteristic of the syndrome.
HGPS is caused by mutations in the gene encoding lamin A, a key component of a matrix of proteins that lie just inside the cell's nuclear membrane. At an early age, those born with such mutations develop osteoporosis, atheroscelerosis, wizened skin, hair loss, and other features typical of the elderly. Scientists have also noticed that the cell nuclei of HGPS patients bulge in odd ways, apparently because the abnormal lamin A generated by the mutation accumulates near the nuclear membrane and distorts it.
Enzymes called farnesyltransferases help lamin A get to the nuclear membrane in the first place, so Francis Collins of the National Human Genome Research Institute (NHGRI) in Bethesda, Maryland, and others speculated that inhibiting these enzymes could help HGPS patients. Earlier this year, a group led by Stephen Young and Loren Fong, both of the University of California, Los Angeles, showed that such inhibitors, originally designed to keep farnesyltransferases from activating cancer-promoting proteins, could reverse the misshapen nuclei in cells from mice with mutations in the lamin A gene.
Now, in a paper published online this week in Proceedings of the National Academy of Sciences (PNAS), the group reports similar results with skin cells from HGPS patients. In a second PNAS paper, Collins, along with NHGRI's Brian Capell and colleagues, report comparable findings.
While it's not yet known if these drugs can slow or cure the disorder in humans, scientists are so encouraged by the cell studies that they are readying plans for a clinical trial next year. "I figured this was a long shot, and at best you might see a small effect," says Collins. "Instead, what you see, looking at the shape of the nucleus, is that you can cure these cells."
Still, Collins, Young, and others caution that it's not proven that the nuclear distortions cause the premature aging disease. Cell biologist Robert Goldman of Northwestern University Institute for Neuroscience in Chicago agrees. "I'm not sure [preventing] misshapen nuclei alone is the answer," he says, noting that lamins have many roles beyond giving the nucleus its spherical form.